Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cd34+cxcr4+ autologous bone marrow cells
- Development stage
- Unknown
- Lead developer
- Lisata Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
CD34+CXCR4+ autologous bone marrow cells are a specialized population of progenitor cells harvested from a patient's own bone marrow and selected for the expression of CD34 and CXCR4 surface markers. CD34 is a marker for hematopoietic and endothelial progenitor cells, while CXCR4 (C-X-C chemokine receptor type 4) is the receptor for stromal cell-derived factor 1 (SDF-1), which plays a critical role in the homing of these cells to ischemic or injured myocardium. This cell therapy was investigated in the REGENT trial (NCT00316381) for the treatment of acute myocardial infarction (AMI) in patients with reduced left ventricular ejection fraction. The cells are typically delivered via transcoronary infusion to promote myocardial repair and angiogenesis. Clinical evaluations using intravascular ultrasound have demonstrated that the administration of these cells is safe and does not promote the progression of coronary atherosclerosis, potentially even contributing to a reduction in plaque burden.
- Other names
- CD34+CXCR4+ autologous bone marrow cellsCD34+CXCR4+ cellsautologous bone marrow-derived selected CD34+CXCR4+ cellsselected CD34+CXCR4+ bone marrow cells
Beyond the preview
Go deeper on cd34+cxcr4+ autologous bone marrow cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cd34+cxcr4+ autologous bone marrow cells.